

INDEX

- Abortifacients, 850
Acyclovir, 1037–1042
Adjuvants, 635–637
ADMET, 8–9
AERx, 709–710
AIDS, 4
Alginate nanoparticles, 540–541
Alginic acid, 295
Anticancer drug delivery, 485–506
Antimicrobials, 845–846
API, 5
Artificial neural networks, 1016
Aseptic compounding, 107–108
Auxiliary excipients, 894–895
Avonex, 47
Aztirelin, 620
- Bentonite, 295
Benzodiazepines, 623–626
Betaseron, 47
Bioadhesion, 305–306
Bioburden considerations, 26
Bioconversion, 566, 572–574
Biodegradable microspheres, 419–426
Biodegradable polymeric nanoparticles, 536–543
Biodrug, 565–566
Biogenerics, 35
- Biological half-life, 356
Biopharmaceuticals Classification System (BCS), 237–238, 961
Boron Neutron Capture Therapy (BNCT), 489
Breast cancer, 492–497
Breath actuation, 698–699
- CaCo-2, 960
Caelyx, 497
Calcitonin, 613–617
Cancer therapy, 1238–1240
Capillary Aerosol Generator (CAG), 710–711
Carbomer, 295–296
Carbxyethyl cellulose, 655
Carnauba wax, 274
Carr index, 908
Carrageenan, 296, 833
Challenges in ocular drug delivery, 730–737
Characteristics of radiopharmaceuticals, 60–61
Chemical penetration enhancers, 803
Chemically induced release, 384–385
Chitosan nanoparticles, 541
Chitosan, 608, 636, 655, 657, 658, 661–662, 665–666, 833

- Cholera toxin, 637
Ciliotoxicity, 668
Classification of hygroscopicity, 912
Climatization, 1085–1086
CMV, 481
Coated tablets, 244–245
Colloidal silicon dioxide, 296
Colorants, 243
Compactibility, 1138–1141
Compendial gels, 307
Compendial ointments, 289–291
Compressibility, 917–918
Container closure systems, 17–18
Controlled-release delivery systems, 11
Cryogenic spray drying, 401–402
Cytotoxicity, 1240
- Definitions of density terms, 1178
Dendrimers, 1272
Depyrogenation, 117–120
Diluents, 240–241
Diphtheria Toxoid (DT), 420–421
DirectHaler, 602–604
Disintegration, 920–922
DPI, 689
Drug product stability, 21–25
Drug-excipient compatibility, 969–970
Dry Powder Inhalers (DPIs), 684, 700–706
- Effective half life, 61
Effervescent tablets, 251–252
Electroresponsive release, 381–383
Ethylcellulose, 297
Excipients, 1344, 19–21, 239–244, 243–244, 410–412, 412–419, 695, 822–823, 883–896, 884–885, 897
Exubera, 704, 705–706
- Fair Packaging and Labeling Act, 190–195
FDA-approved transdermal patches, 794
First-uterine-pass effect, 821
Fluidized-bed coating, 1102–1103
FluMist, 592
Formulation approaches to improve ocular bioavailability, 737–753
Formulation assessment, 7–8
Formulation development, 15–16, 238
Fortical, 52–53, 55
Friability, 928
Fullerenes, 1272, 1296–1297
- Gas and vapor sterilization, 119
Gastrointestinal tract and absorption, 356–357
Gelatin capsules, 245–251
Gelatin, 539
Gelling agents, 293–301
GELS, 288–310
Giladin, 540
Glucose-responsive insulin release device, 384–385
Glycerol behenate, 298–299
Group B streptococcus vaccine, 420
Guar gum, 297
- Hammer Mill, 1169
Hausner ratio, 908
Herpes simplex virus, 481
HFA reformulation, 690–692
High-throughput Screening (HTS), 934
Human Growth Hormone (HGH), 34
Hyaluronic acid, 499, 655, 657, 833
Hydralazine, 627
Hydrogels, 291–292
Hydrophilic matrix tablets, 1210–1211
Hydroxyethyl Cellulose (HEC), 297–298
Hydroxypropylmethyl Cellulose (HPMC), 298
- Immunity after intranasal immunization, 634–635
Immunogenicity, 50, 53–54
Inhalation drug products, 179
Injectable microspheres, 407–408
Insulin, 424–426
Ionophoresis, 804
- Japanese Encephalitis Virus (JEV), 423–424
- Kurve Technology, 601
- Labor inducers, 850
Lanolin, 271
Lipinski Rule of Five, 934
Liposomal drugs approved for clinical application, 1263
Liposome-based products currently under clinical testing, 484
Liposomes, 365–367, 636, 747–748
Liquid dosage forms, 338
Low-molecular-weight heparins, 617–620
Lozenges, 252–253

- Lung cancer, 497–502
 Lung toxicity, 1309–1310
 Lyophilization, 127–128
- Magnetically induced release, 383–384
 Marked medical and nonmedical emulsions, 1332
 MDI, 689
 Mechanisms of protein and peptide degradation, 22–23
 Metal as packaging material, 170–171
 Metered-dose Inhalers (MDIs), 684, 690–700
 Microbicides, 843–845
 Microbiological quality, 334–335
 Microcrystalline cellulose (MCC), 653, 655
 Microemulsions, 1267, 748–750
 Microencapsulation, 358
 Microneedles, 803–804
 Milestones in early biologics regulation, 38
 MLVs (multilamellar vesicles), 444
 Mononuclear phagocyte system, 1333
 Mucoadhesion, 840
 Mucoadhesive microspheres, 657
 Mucoadhesive polymers, 744
 Mucosal toxicity screening method using the slug arion lusitanicus, 667
 Mucosal-associated lymphoid tissue (MALT), 635
 Musciliary clearance, 596
- Nanocapsules, 363
 Nanocarriers, 1258–1273
 Nanoemulsions, 1269
 Nanogels, 1271
 Nanomaterials in pharmacy, 1253–1254
 Nanomaterials, 1250–1252
 Nanomedicine technologies taxonomy, 1292–1293
 Nanomedicine, 1278–1279
 Nanoparticles, 1231–1236, 1264–1269, 536, 746–747
 Nasal delivery, 481–482
 Nasal delivery of nonpeptide molecules, 622–630
 Nasal delivery of vaccines, 633–637
 Nasal dry powder formulations, 652–655
 Nasal route, 1352–1353
 Nasal vaccination delivery systems, 636–637
 Nasal vasculature, 594–595
 Nebulizers, 706–707
- Niosomes, 367, 748
 Nitroglycerin, 627–628
 Noncovalent binding of ligands, 465–466
 Nose-associated Lymphoid Tissue (NALT), 635
 Nose-to-Brain Delivery, 632
- Ocular delivery, 477–481
 Ocular drug delivery, 738–741, 784–785
 Ocular routes, 1347–1352
 Official creams, 282
 Official gels, 304
 Oil-in-water nanosized emulsions, 1329–1341
 Ointments and creams, 269–270
 Omnitrope, 51, 53–56
 OptiNose, 601–602
 Oral drug delivery, 781–782
 Oral ER formulations, 1193–1195
 Orally disintegrating tablets, 259–262
 Organogels, 292
 Ovarian cancer, 502–506
- Pan coating, 1102
 Parenteral drug delivery, 783–784
 Parenteral routes, 1346–1347
 Partition coefficient, 352, 956–957
 PEGylated liposomes, 469–472
 Percolation theory, 1013–1016, 1030–1042
 Permeability enhancement methods, 964
 Preservatives, 20–21
 PET radiopharmaceuticals, 83
 Petrolatum, 272
 Photostability, 23
 pH-sensitive polymeric nanoparticles, 547
 Physicochemical properties of liposomes, 449–456
 Plastic additives, 164
 Plastic as packaging material, 166–170
 Poloxamer, 299
 Poly (lactic acid), 543–544
 Polyethylene oxide, 299–300
 Polymorphism, 936–942
 Polysaccharides, 539–540
 Polyvinyl Alcohol (PVA), 300
 Povidone, 300
 Preformulation approaches for tablet production, 883
 Principles for extended drug release, 1196–1197
 Principles of radiation protection, 63–64
 Production of radionuclides, 75–76

- Production of radiopharmaceuticals, 78–88
Propylene Glycol Alginate (PGA), 300
- Quantum dots, 1293–1295
- Radiation sterilization, 119
Radioactive decay, 61–63
Radiochemical purity, 90–91
Radionuclides, 65
Reaction calorimetry, 141–142
Respmat, 708–709
Route of administration, 8–10
- Salmon calcitonin, 52
Salt selection, 952–956
Scanning tunneling microscopy, 1306–1308
Selected drugs administered in vagina, 853
Selection guideline of pharmaceutical excipients, 895–896
Selection of microemulsion ingredients, 773
Sodium alginate, 300–301, 538, 655
Soft Mist Aerosols, 707–708
Solubility characteristics, 950–965
Sonophoresis, 804
Spermicides, 849–850
Stability, 336–337
Stability-indicating methodologies, 14–15
Stability of liposomes, 455–456
Sterile products, 169–170
Sterilization, 117–120
Sterilization by filtration, 119–120
Sterilization of radiopharmaceuticals, 73–74
Surface hydrophilicity, 550
Synthesis of PET radiopharmaceuticals, 86
- Synthetic cervical mucus, 816
Systemic uptake of nanoparticles, 1310–1311
- Tablet coating methods, 1102–1103
Tablet tooling terminology, 1147
Tableting machines, 1058–1067
Tableting process, 1055–1056
Tetanus toxoid, 421–423
Thermoresponsive drug release dosage forms, 379–381
Thermosensitive polymeric nanoparticles, 546–547
TNO gastrointestinal tract model, 569–571
Topical route, 1353–1355
Toxicological effects of dry powder formulation, 666–667
Tragacanth, 301
Transdermal drug delivery, 368, 782–783
- Ultrasonic atomization, 403
Ultrasound-assisted tableting, 1043–1045
United States Pharmacopoeia Center for the Advancement of Patient Safety, 195
U.S. Pharmacopoeia, 177
USP, 281–282, 304, 903
- Vaccines, 420–424, 851–852
Vaginal and uterine controlled-release dosage forms, 371
Vaginal films, 831
Vaginal fluid stimulant, 816
Vaginal foams, 831
Vaginal rings, 826–830
Vaginal sponges, 832
Vibrio cholerae vaccine, 423